IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

GE HealthCare Plans $945 Million SOFIE Acquisition — Oct 5, 2026GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical manufacturing and distribution network and strengthening its position in the growing precision-imaging market. The deal, expected to close in the first half of 2027 pending regulatory approval, also gives GE HealthCare U.S. rights to the Phase III imaging agent FAPI-74.

0

Zydus Lifesciences plans Phase III Desidustat trial sickle cell ICMR — Jul 23, 2026Zydus Lifesciences has received regulatory approval to initiate a 203-day Phase III trial of Desidustat for sickle cell disease in collaboration with ICMR, enrolling 164 patients to assess efficacy and safety of the oral tablet. The move follows successful Phase II results and US FDA Orphan Drug Designation, underscoring a public-private effort to address India's substantial SCD burden.

0

Commentary: Dr. Fauci: It’s ‘Still Not OK’ for Vaccinated Americans To Eat and Drink IndoorsReporting — Apr 12, 2021From the very beginning, I was one of the people most excited about the coming COVID-19 vaccines. I have mentioned several times that I was a participant in Moderna’s Phase III trial, and the thought that I contributed…

0

AstraZeneca Ends Phase III Lung Cancer Trial — Aug 17, 2026AstraZeneca reports a setback as its Phase III trial of volrustomig plus chemotherapy in PD-L1 negative metastatic non-small cell lung cancer is halted after an independent data review found it unlikely to meet primary endpoints, while another late-stage study in cervical cancer and other indications continues. In a positive contrast, AZN and partners SAFFRON showed that Tagrisso combined with Orpathys significantly improved progression-free and overall survival, underscoring a mixed near-term outlook but ongoing strength in its immuno-oncology pipeline.

0

IJRFBI Nabs Saudi National Accused Of Hiding Bug In Toilet Paper To Spy On AI Giant’s Inner SanctumDylan Kresak · 3 min · 1h

Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint — Sep 5, 2026Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.

+2

Jared Kim Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.

AP Top 25 College Football TeamsRankingCollege football fans argue endlessly over which programs deserve the top spots in the AP Poll based on wins, schedule strength, and legacy.

Lancet study finds 45% of dementia cases could be prevented despite diagnosis delays — Sep 6, 2026A Lancet study suggests as many as 45% of dementia cases could be prevented or delayed through modifiable risk factors such as smoking, diet, exercise, hearing/vision care, and social engagement, reinforcing the idea that heart and brain health are tightly linked. Meanwhile, reports from the UK highlight long delays in dementia diagnosis and the strain on families, even as a Phase III trial explores biomarker-based prevention before symptoms appear, underscoring the need for scalable diagnostic infrastructure and timely support.

0

Hutchmed Secures NMPA Approval for ATLED ICCHealth — Aug 28, 2026HUTCHMED announced conditional NMPA approval for ATLED (fanregratinib), an FGFR1/2/3 inhibitor, to treat adult patients with advanced FGFR2-fusion intrahepatic cholangiocarcinoma after prior systemic therapy, with China commercialization planned under the ATLED name. The pivotal data show a 42.5% objective response rate, rapid onset, and durable disease control, supporting a Phase IIIb confirmatory program alongside ongoing commercialization in China.

0